

Review Article

Phyllanthus urinaria: a potential phytopharmacological source of natural medicine

Guankui Du^{1*}, Man Xiao^{1*}, Siman Yu², Mengyi Wang², Yiqiang Xie², Shenggang Sang²

¹Department of Biochemistry and Molecular Biology, Hainan Medical College, Haikou 571101, China; ²First Affiliated Hospital of Hainan Medical College, Haikou 571199, China. *Equal contributors.

Received December 14, 2017; Accepted May 20, 2018; Epub July 15, 2018; Published July 30, 2018

Abstract: *Phyllanthus urinaria* is an herb species in the family Euphorbiaceae. *P. urinaria*, which grows mainly in tropical regions such as India, Sri Lanka, Indochina, Japan, Malaysia, Indonesia and the United States, has long been used in traditional oriental medicine for the treatment of liver damage, hepatitis, jaundice, renal disorders, enteritis, diarrhea, and dropsy. Experimentally, *P. urinaria* displays antiviral, anti-tumor, hepatoprotective, anti-diabetic, antioxidant, anti-hypertensive, anti-inflammatory, and anti-microbial effects. Phytochemical screening revealed the presence of flavonoids, carboxylic acids, tannins, coumarins, and lignans in *P. urinaria* extracts (PUE). Meanwhile, PUE possess various pharmacological and biological activities. This study summarizes the ethno-medical use, chemical constituents, and pharmacological profile of *P. urinaria*. As a medicinal plant, this herb has emerged as a good source of traditional medicines. However, the composition-activity relationship for this plant deserves further research.

Keywords: *Phyllanthus urinaria*, chemical constituents, antiviral, antitumor, liver protection

Introduction

Phyllanthus urinaria L. (*P. urinaria*), commonly called chamber bitter, is an herb species in the family Euphorbiaceae [1, 2]. Numerous small green-red fruits are found along the underside of its stems. Therefore, the plant is called “YeXiaZhu” in the Pharmacopoeia of the P. R. of China [1]. *P. urinaria* has the features of great number of seeds, high shade tolerance, and extensive root system, and is therefore considered a competitive weed. It is widely found in all tropical regions of the world, including India, Sri Lanka, Indochina, Japan, Malaysia, Indonesia, and the United States.

The whole plant could be used as medicine. As a natural product, *P. urinaria* has long been used in traditional oriental medicine to promote healthy elimination of gallstones and kidney stones, as an immune system inducer, and for liver disease treatment [3, 4]. Evidence indicates that *P. urinaria* extracts possess numerous biological activities (**Figure 1**), including cardioprotective [5], anti-hypertensive [6], anti-plasmodial [7], and antioxidant [5, 8] effects.

Very recently, the anti-tumor [9], anti-inflammatory [10] and anti-microbial [11] activities of *P. urinaria* were reported. In addition, *P. urinaria* extracts show antiviral activities against hepatitis B virus (HBV) [12-14], herpes simplex viruses (HSV) [15-19], dengue virus [20], enteroviruses [21], hepatitis B virus (HCV) [22], and human immunodeficiency virus (HIV) [23-25]. This herb is also used as traditional medicine for its protective effects against liver disorders [26, 27]. In this review, the beneficial properties of *P. urinaria* and its active components were discussed, so that the potential use of this plant as pharmaceuticals or an agricultural resource can be readdressed.

Ethnopharmacology

As a Chinese folk medicine, *P. urinaria* is used for the treatment of liver damage, hepatitis, jaundice, renal disorders, enteritis, diarrhea, and dropsy [28]. *P. urinaria* was shown to have hypoglycemic effects in northern Thailand [29]. In addition, the herb has long been used for liver protection, diabetes, hepatitis, jaundice, and dropsy in India [3]. Furthermore, *P. urinaria*



Figure 1. Schematic effects of *Phyllanthus urinaria* and its active constituents in metabolic syndrome together with some relevant mechanisms.

juice is used for tongue cleaning, appetite stimulation in children, and malaria treatment in Malaysia [30]. The roots and stem of this plant have been used as natural medicine for the treatment of diabetes, hepatitis B virus, and kidney and urinary bladder problems in Korea [31]. Moreover, *P. urinaria* is an important medicinal plant in Indonesia, and traditionally used to treat diseases related to urinary problems, such as kidney stones, and urinary tract infections and malfunction [32]. Meanwhile, *P. urinaria* is used for diabetes and diarrhea treatment in Trinidad and Tobago [33].

Phytochemistry

Multiple functional compounds with medicinal effects, such as flavonoids, carboxylic acids, tannins, coumarins, and lignans, have been isolated from *P. urinaria* (Table 1). In 1993, Yao QQ *et al.* isolated 11 compounds from *P. urinaria* [34]. So far, about 76 compounds have been isolated and identified in this plant.

Polyphenols

Polyphenols are considered the main bioactive compounds in *P. urinaria*, and include 9 flavonoids and 17 tannins. Flavonoids constitute the major chemical components of *P. urinaria*. In 1993, quercetin, rutin and kaempferol were isolated from whole plant extracts of *P. urinaria* [34]. Then, quercetin 3-O-b-D-glucoside, kaempferol 7-methyl ether, rhamnocitrin, and naringin were further isolated from this plant [10, 35, 36]. In addition, two new acetylated flavonoid glycosides, including quercetin 3-O- α -L-(2,4-di-O-acetyl) rhamnopyranoside-7-O- α -L-rhamnopyranoside and quercetin 3-O- α -L-(2,4-di-O-acetyl) rhamnopyranoside-7-O- α -L-rhamnopyranoside, alongside quercetin 3-O- α -L-rhamnopyranoside, were identified [37].

Tannins

Tannins are also very abundant in *P. urinaria*. Zhang LZ *et al.* isolated a novel polyphenolic

Natural medicine *Phyllanthus urinaria*

Table 1. Chemical constituents of *Phyllanthus urinaria*

Category	Type	Compounds	Reference
Polyphenols	Tannins	Excoecarianin	[40]
		Trimethyl-3,4-dehydrochebulate	[10]
		Phyllanthusiin C	[41]
		Epigallocatechin, epicatechin-3-gallate, epicatechin, epigallocatechin-3-gallate	[42]
		Gallocatechin-3-gallate	[36]
		Repandinin B, Furosin, Repandusinic acid A, Mallotinin, Geraniin, Acetonylgeraniin D, Corilagin	[35]
		phyllanthusin F, phyllanthusiin G	[43]
		Rhamnocitrin	[10]
	Flavonoids	Rutin, quercetin	[10, 36]
		Naringin	[36]
		Quercetin 3-O- α -L-(2,4-di-O-acetyl) rhamnopyranoside-7-O- α -L-rhamnopyranoside, quercetin 3-O- α -L-rhamnopyranoside	[37]
		Quercetin 3-O-b-D-glucoside, Kaempferol 7-methyl ether	[35]
		Kaempferol	[34]
		Ellagic acid, Brevifolincarboxylic acid	[41]
		Methyl brevifolincarboxylate	[10, 34]
Phenylpropanoid	Coumarin	Ethyl brevifolincarboxylate	[34]
		Phyllanthin, hypophyllanthin, nirtetralin, niranthin, phylltetralin,	[45]
		(+)-dihydrocubebin, (+)-lyoniresiol, (7R,7'R, 8S, 8'S)-icariol A2, evofolin B, 4-oxopinoresinol, (-)-syringaresinol, (-)-episyngaresinol	[44]
	Lignans	Virgatusin, lintetralin, 5-demethoxyniranthin, urinatetralin	[45]
		Ferulic acid, p-hydroxybenzaldehyde, 3,5-dihydroxy-4-methoxybenzoic acid, dehydrochebulic acid trimethyl ester	[44]
		Gallic acid, methyl gallate	[10, 36]
	Phenols	Cloven-2 β , 9 α -diol	[44]
		(6R)-menthialolic acid	[44]
		Cleistanthol, Spruceanol	[44]
		28-norlup-20(29)-ene-3,17 β -diol, Betulin, β -betulinic acid, 3-oxo-friedelan-28-oic acid, oleanolic acid, 3R-E-coumaroyltaraxerol, 3R-Z-coumaroyltaraxerol	[46]
Terpenoids	Sesquiterpene	Glochidiol, oleanolic acid	[44]
	Monoterpene		
	Diterpenoids		
	Triterpenoids		
Volatile oils	Jasmonate derivatives	(+)-cucurbitic acid, (+)-methyl cucurbate, methyl[1R,2R,2'Z]-2-(5'-hydroxy-pent-2'-enyl)-3-oxocyclopentaneacetate	[44]
	Aldehyde derivative	5-hydroxymethyl-2-furaldehyde	[44]
Glycosides	Glycosides	β -sitosterol-3-O- β -D-glucopyranoside	[10]
		Gentisic acid 4-O-b-D-glucopyranoside, Syringin	[35]
Steroids	Steroids	β -sitosterol, [3 β , 22E]-stigmasta-5,22-diene-3,25-diol	[44]
		daucoesterol	[34]

compound phyllanthusin F [38] and an ellagitannin termed phyllanthusiin G was also reported [39]. Further bioassay-guided purification of *P. urinaria* extracts (PUE) led to the isolation of 7 ellagitannins, including repandinin B, furosins, repandusinic acid A, mallotin, geraniin, acetylgeraniin D, and corilagin [35]. Meanwhile, Tseng HH reported 4 tannins, including epicatechin, epigallocatechin-3-gallate, epicatechin-3-gallate and galocatechin-3-gallate. Recently, 4 major compounds, including excoecarianin, phyllanthusiin C, epigallocatechin, and trimethyl-3,4-dehydrochebulate were identified as a plant fingerprint by HPLC/MS [10, 40-42].

Phenylpropanoids

Phenylpropanoids are considered the major bioactive class among *P. urinaria* compounds, and include coumarin, lignans, and phenols. Studies reported 4 coumarin compounds, including ellagic acid, methyl brevifolincarboxylate, ethyl brevifolincarboxylate, and brevifolincarboxylic acid [34, 41, 43]. In addition, 6 phenols (dehydrochebolic acid trimethyl ester, ferulic acid, p-hydroxy-benzaldehyde, 3,5-dihydroxy-4-methoxybenzoic acid, gallic acid, and methyl gallate) were isolated and identified [10, 34, 36, 41, 44].

Lignans constitute the major class of phenylpropanoid compounds. Hu et al. identified 7 lignans, including (+)-dihydrocubebin, (+)-lyoniresinol, (7R,7'R, 8S, 8'S)-icariol A2, evofolin B, 4-oxopinoresinol, (-)-syringaresinol, and (-)-epi-syringaresinol, from this plant [44]. Moreover, Wang CY et al. characterized several lignans from *P. urinaria* by HPLC-SPE-NMR, including hypophyllanthin, phyllanthin, phyltetralin, nirtetralin, niranthin, virgatusin, lintetralin, 5-demetoxyniranthin and urinatetralin [45].

Terpenoids

Hu et al. isolated 2 triterpenoids (glochidiol and oleanolic acid), 2 diterpenoids (cleistanthol and spruceanol), 1 sesquiterpene (cloven-2 β , 9 α -diol), 1 monoterpene [(6R)-menthiafolic acid] from whole plant extracts of *P. urinaria* [44]. Wu Y et al. isolated 7 triterpenoids from *P. urinaria*, including 28-norlup-20(29)-ene-3,17 β -diol, betulin, β -betulinic acid, 3-oxofriedelan-28-oic acid, oleanolic acid, 3R-E-coumaroyltaraxerol, and 3R-Z-coumaroyltaraxerol [46].

Other compounds

A number of other compounds have been isolated from *P. urinaria*, including glycosides, volatile oils, and steroids. β -sitosterol-3-O- β -D-glucopyranoside, gentisic acid 4-O- β -D-glucopyranoside and syringin are the main glycosides isolated from *P. urinaria* (Table 1). In 2007, gentisic acid 4-O- β -D-glucopyranoside and syringin were obtained from whole plant extracts of *P. urinaria* [35]. Then, in 2008, β -sitosterol-3-O- β -D-glucopyranoside was isolated from this plant [10]. Meanwhile, 4 essential oil components, including the 3 jasmonate derivatives (+)-cucurbitic acid, (+)-methyl cucurbate, methyl (1R,2R,2'Z)-2-(5'-hydroxy-pent-2'-enyl)-3-oxocyclopentaneacetate, and the aldehyde derivative 5-hydroxymethyl-2-furaldehyde, were isolated from *P. urinaria* [44]. In addition, three Steroids, including β -sitosterol, (3 β , 22E)-stigmasta-5,22-diene-3,25-diol and daucosterol were recently isolated from *P. urinaria* [34, 44].

Pharmacological properties *P. urinaria*

Antiviral effects

Anti-HBV activity: Despite the availability of effective vaccination programs, HBV infection remains a major world health problem, with about 400 million people affected worldwide [47]. It was demonstrated that *P. urinaria* has good effects on hepatitis B treatment. Indeed, studies reported that PUE markedly inhibit intracellular HBsAg formation [48-50] and repress HBsAg and HBcAg secretion [50, 51]. PUE also significantly reduce HBV DNA levels by inhibiting its synthesis and secretion in HBV infected cells [51, 52]. In *in vivo* experiments, Wu Y et al. demonstrated that PUE markedly repress HBV replication and expression in a HBV transient transfection mouse model [50]. Chen YX et al. showed that PUE significantly reduce serum DHBV DNA in a duck model of HBV infection [53]. In clinical trials, Wang MX et al. demonstrated that *P. urinaria* promotes HBeAg and HBeAb seroconversion from positive to negative in a total of 35 patients with chronic hepatitis B [54]. Tong GD et al. showed that *P. urinaria* effectively decreases HBV-DNA levels, prevents or delays the development of HBV-associated cirrhosis into HCC in 52 patients [55].

P. urinaria compounds exhibit antiviral activities against hepatitis B virus infection [49, 56]. Zhong Y et al. showed that methyl ester dehydrochebulic acid and methyl brevifolin carboxylate possess antiviral activities against HBV [49]. Shin MS et al. identified the flavonoid ellagic acid, which effectively inhibits HBeAg secretion in HepG2 2.2.15 cells (IC₅₀ = 70 µg/ml) [56].

Anti-HSV properties: HSV is one of the most common sexually transmitted diseases worldwide [57, 58]. HSV is a single large double-stranded DNA enveloped virus [58, 59]. In 2005, Yang CM et al. assessed the anti-HSV-1 and HSV-2 activities of different solvent extracts from *P. urinaria* *in vitro* by plaque reduction assay [16]. The results showed that acetone, ethanolic, and methanolic extracts of *P. urinaria* inhibit HSV-2 but not HSV-1 infection. All 3 extracts likely inhibit HSV-2 infection by altering the early stage of viral infection, diminishing virus infectivity [16].

Further studies demonstrated that Hippomanin A and excoecarianin from the acetone extract of *P. urinaria* effectively repress HSV-2 but not HSV-1 infection *in vitro* [19, 40]. Excoecarianin could inactivate HSV-2 virus particles [40]. Meanwhile, geraniin and 1,3,4,6-tetra-O-galloyl- β -D-glucose, isolated from the acetone extract of fresh whole plants, inhibit HSV-1 and HSV-2 infection [18]. Corilagin markedly represses HSV induced brain pathological alterations in an animal model [60]. Corilagin markedly suppresses HSV induced inflammatory cytokines, including TNF- α and IL-1 β [60]. Furthermore, findings demonstrated that corilagin protects from HSV-1 encephalitis by inhibiting the TLR2 pathway [61]. Moreover, proteomics showed that *P. urinaria* might affect cytoskeletal protein expression at the early infection and replication stages [62]. Therefore, *P. urinaria* represents a plant that can potentially be used as an alternative anti-herpetic drug.

Other antiviral effects: HCV is associated with several hepatic and extra hepatic disorders, including malignancies [63]. Chung et al. found that the acetone extract of *P. urinaria* alters specific steps of the viral life cycle [22]. They further found its bioactive component loliolide potentially inhibits HCV entry [22].

HIV is a lentivirus that causes acquired immunodeficiency syndrome [64]. Zhang et al. demonstrated the polyphenolic extract and gallic acid from *P. urinaria* have anti-HIV-1 activities [65]. In addition, the polyphenolic extract and gallic acid interact with HIV-1 RT, gp120, and P24 [65]. These properties and the anti-HIV-1 activities render the plant interesting for further studies.

Human enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are major causative agents of hand, foot, and mouth disease (HFMD), especially in infants and children under 5 years of age. Yeo et al. showed that corilagin reduces EV71 or CA16 induced cytotoxicity in Vero cells, with significant antiviral activities against EV71 and CA16 [21].

Epstein-Barr virus (EBV) is a gamma herpes virus that modulates the expression of viral genes. Liu KCSC et al. showed that gallotannin, corilagin, ellagic acid, and 7 ellagitannins isolated from *P. urinaria* could inhibit Epstein-Barr virus DNA polymerase [66].

Anti-tumor effects of *P. urinaria*

In recent years, advances in the anti-tumor effects of *P. urinaria* have been reported. Studies showed that PUE significantly reduce viability in various cancer cell lines [67-70], inducing apoptosis in human cancer cells [71]. The methanolic extract of *P. urinaria* shows higher cytotoxicity in A549 and MCF-7 cells compared with the water PUE [72, 73]. *P. urinaria* extracts, which contain polyphenols such as gallic acid, methyl gallate, epicatechin, epigallocatechin-3-gallate, gallocatechin-3-gallate, rutin, epicatechin-3-gallate, and naringin, markedly inhibit cell invasion and migration [36]. *P. urinaria* also plays a role in angiogenesis *in vivo* [74, 75].

Lung cancer: Lung cancer constitutes one of the malignancies with the greatest incidence and mortality rates, with 1.6 million new cases and 1.4 million deaths recorded yearly [76]. *P. urinaria* exhibits anti-tumor and anti-angiogenic effects in mice with Lewis lung carcinoma. Treatment with PUE significantly inhibits tumor development, with lower occurrence rate and markedly reduced tumor size in mice [69]. Furthermore, tumor neovascularization is repressed by *P. urinaria*-treatment [69]. PUE trig-

ger apoptosis through Bcl-2 downregulation and increased caspase-3 activity in Lewis lung carcinoma cells [67, 68]. Moreover, PUE inhibit A549 metastasis by suppressing ERK1/2 and hypoxia pathways [72, 73]. Tseng HH et al. demonstrated that PUE inhibit metastasis by suppressing MMP-2, MMP-9, and urokinase plasminogen activator, as well as their endogenous inhibitors, i.e. tissue inhibitor of metalloproteinase-2 and plasminogen activator inhibitor-1 [36]. *P. urinaria* also exhibits anti-angiogenic activity by suppressing MMP-2 secretion and inhibiting MMP-2 activity [67]. Therefore, *P. urinaria* could be used as alternative anti-lung tumor drug.

Human osteosarcoma: Human osteosarcoma is one of the toughest malignancies, with few therapeutic modalities [77]. *P. urinaria* inhibits human osteosarcoma cell growth through the extrinsic apoptotic pathway, activating Fas receptor/ligand expression [78]. Meanwhile, PUE repressed Saos-2 cell invasion and migration by inhibiting u-PA via ERK and Akt signaling pathways [79]. Huang ST et al. demonstrated that PUE modulate the mitochondrial dynamics via fusion and fission machineries [70, 80].

Melanoma: Melanoma is the most dangerous type of skin cancer [81]. *P. urinaria* represses melanin formation in melanoma B16 cells [82]. Further studies showed that *P. urinaria* prevents tumor proliferation, metastasis, and angiogenesis by inhibiting MAPKs, Myc/Max, NF-kappaB, and hypoxia pathways in human melanoma cells [83]. Bharali R et al. suggest a possible chemopreventive property of *P. urinaria* in skin papillomagenesis in mice [84].

Hepatocellular carcinoma (HCC): HCC is a highly prevalent health risk, and the third leading cause of cancer related deaths worldwide [85]. Blumberg et al. found that PUE can significantly reduce the liver cancer rate in woodchucks, indicating the overt anti-hepatoma effects of *P. urinaria* [12]. Chudapongse N found that the water-methanolic extract of *P. urinaria* induces cell death in HepG2 cells, in a dose-dependent fashion. This extract profoundly reduces state 3 respirations and the respiratory control ratio [86]. The authors concluded that *P. urinaria* impairs energy metabolism to fight hepatocellular carcinoma [86].

Breast cancer: Breast cancer is the leading type of cancer in women, accounting for 25% of

all malignancy cases in females [87]. Lee et al. found that *Phyllanthus* spp. can induce apoptosis, in association with caspase-3 and -7 activation, as well as DNA fragmentation, in A549 and MCF-7 cancer cell lines [73]. Moreover, *P. urinaria* induced apoptosis is mediated by ROS-mediated stimulation of p38 MAPK signaling in the human breast cancer MCF-7 cell line [88].

Prostate Cancer: Prostate cancer is the second most common malignancy and the fifth leading cause of cancer-related death in men [89]. *P. urinaria* induces selective growth inhibition of human cancer PC-3 and MeWo cells through cell cycle modulation and apoptosis induction [90]. Further studies showed that *P. urinaria* suppresses prostate cancer cell proliferation and induces apoptosis through multiple signaling pathways, including MAPK, PI3K/Akt, NF-kappaB, and Hypoxia pathways [90].

Nasopharyngeal carcinoma (NPC): NPC is a common cancer in Taiwan, Hong Kong and southern China [91]. Huang ST et al. (2009) demonstrated that *P. urinaria* reduces NPC-BM1 cell growth *in vitro* through induction of Bax/Bcl-2-mediated apoptosis and reduction in telomerase activity via c-myc signaling [41].

Hepatoprotective effects

Phyllanthus species are well known for their hepatoprotective activities [92, 93]. In an animal model of CCl₄-induced acute liver damage, *P. urinaria* significantly reduces ALT, inhibits oxidative stress, increases membrane mobility, and decreases liver infiltration and focal necrosis [94, 95]. Further, metabolomics studies identified 17 biomarkers, including L-carnitine, taurocholic acid, and amino acids, in CCl₄-induced rats treated with PUE [28]. Moreover, it was shown that *P. urinaria* possesses a dose-dependent hepatoprotective activity in acetaminophen/tert-butyl hydroxide/methionine-and-choline-deficiency induced hepatotoxicity, possibly through inhibition of cytochrome P450, oxidative stress, inflammation, and lipid accumulation [96-98].

The hepatoprotective effects of *P. urinaria* could be attributed to corilagin, phyllanthin, and hypophyllanthin, or the combination of various compounds that constitute this extract. Syamasundar KV et al. showed that phyllanthin and hypophyllanthin protect against carbon tetrachloride- and galactosamine-induced cyto-

toxicity in primary cultured rat hepatocytes [99]. Liu et al. showed that corilagin treatment effectively ameliorates neutrophil accumulation, pro-inflammatory mediator production, and increased enzyme release following hepatic injury. Interestingly, blocking Akt activation abolishes the hepatoprotective effects of corilagin [100]. However, in a clinical trial, *P. urinaria* showed no superiority to placebo in improving histological non-alcoholic fatty liver disease (NAFLD) activity scores in 60 patients (40 and 20 treated with PUE and placebo, respectively [101]. The mechanism underlying the hepatoprotective effects of *P. urinaria* is not fully understood, and requires further studies.

Anti-diabetic effects

Diabetes mellitus (DM) is one of the most common diseases in humans. The ethno-medicinal plant *P. urinaria* has been used as herbal anti-diabetic remedies in Vietnam, and Trinidad and Tobago [33, 102]. PUE may exert hypoglycemic effects by enhancing glucose metabolism and/or suppressing glucose absorption in the gut [103]. In addition, it was found that PUE significantly affect amylase [32], and inhibit glucose diffusion across the plasma membrane into blood vessels [104]. Furthermore, compounds isolated from this herb, including gallic acid, corilagin and macatannin B, significantly inhibit α -glucosidase [32, 102].

Anti-oxidative activities

Studies have shown that *P. urinaria* has potential antioxidant agents [5, 10, 35]. Further studies demonstrated that compounds isolated from *P. urinaria* have strong antioxidant activities, e.g. phenolic compounds [35], trimethyl-3,4-dehydrochebulate [10], methyl-gallate [10], methyl brevifolincarboxylate [10], and geraniin [6]. By dampening oxidative stress, this plant may serve as an alternative source of medicine for steatohepatitis alleviation [98], skin disorder treatment [105], skin aging amelioration [106], protection against DOX cardiotoxicity [5, 107], and modulation of phagocyte associated innate immune response [108].

Other activities

Antihypertensive activity: Geraniin from *P. urinaria* displays anti-hypertensive effects, lowering systolic and diastolic blood pressures [6].

Thrombolytic effects: Shen ZQ et al. showed that corilagin has a dose-dependent thrombolytic effect in rats. Meanwhile, corilagin significantly inhibits PAI-1 activity in rat plasma, while increasing plasma tPA activity [4].

Bladder contraction: Dias MA et al. showed that contraction induced by water-ethanolic PUE in the guinea pig urinary bladder involves direct effects on smooth muscle and relies on the mobilization of extracellular calcium influx [109].

Antimicrobial activities: *Helicobacter pylori* is associated with the majority of peptic ulcers and some types of gastric cancer, and shows antibiotic resistance worldwide. Lai CH et al. demonstrated that treatment with PUE markedly inhibits bacterial adhesion and invasion to AGS cells *in vitro*, in a model of *H. pylori* infection. Furthermore, PUE remarkably inhibits *H. pylori*-induced NF- κ B activation and IL-8 release [11].

Materials and methods

Relevant literature was retrieved by searching major scientific databases, including PubMed, Google scholar, and CNKI, for phytochemical, phytopharmacological, and medicinal significance of *P. urinaria*. Additional articles were obtained by tracking citations from the selected publications or directly accessing the journals' websites. Articles were considered based on geographical regions of origin. The literature search included all available reports covering the period from 1988 to 2017.

In summary, through comprehensive assessments in recent studies, the effects of *P. urinaria* (e.g. antiviral, anti-tumor, and liver protective activities) have been demonstrated. Consequently, tablets, granules, capsules, and other formulations based on *P. urinaria* have surfaced, with good curative effects in liver diseases such as hepatitis B. Therefore, exploitation and further evaluation of *P. urinaria* is urgent thanks to its clinical significance and great potential for application. It is believed that broad application of *P. urinaria* with improved treatment effects can be achieved in the future.

Disclosure of conflict of interest

None.

Address correspondence to: Shenggang Sang and Yiqiang Xie, First Affiliated Hospital of Hainan Medical College, Haikou 571199, China. Tel: +86-898-66772248; E-mail: lytssg@126.com (SGS); Tel: +86-898-66893600; Fax: +86-898-66893600; E-mail: xieyiqiang_hy@163.com (YQX)

Reference

- [1] The State Pharmacopoeia Commission of PR China. Pharmacopoeia of the People's Republic of China, vol. 1. Beijing: China Medical Science and Technology Press; 2010.
- [2] Calixto JB, Santos AR, Cechinel Filho V, Yunes RA. A review of the plants of the genus *Phyllanthus*: their chemistry, pharmacology, and therapeutic potential. *Med Res Rev* 1998; 18: 225-258.
- [3] Satyan KS, Prakash A, Singh RP, Srivastava RS. Phthalic acid bis-ester and other phytoconstituents of *Phyllanthus urinaria*. *Planta Med* 1995; 61: 293-294.
- [4] Shen ZQ, Dong ZJ, Peng H, Liu JK. Modulation of PAI-1 and tPA activity and thrombolytic effects of corilagin. *Planta Med* 2003; 69: 1109-1112.
- [5] Chularojmontri L, Wattanapitayakul SK, Herunsalee A, Charuchongkolwongse S, Niumsukul S, Srichairat S. Antioxidative and cardioprotective effects of *Phyllanthus urinaria* L. on doxorubicin-induced cardiotoxicity. *Biol Pharm Bull* 2005; 28: 1165-1171.
- [6] Lin SY, Wang CC, Lu YL, Wu WC, Hou WC. Antioxidant, anti-semicarbazide-sensitive amine oxidase, and anti-hypertensive activities of geraniin isolated from *Phyllanthus urinaria*. *Food Chem Toxicol* 2008; 46: 2485-2492.
- [7] Hout S, Chea A, Bun S, Elias R, Gasquet M, Timon-David P, Balansard G, Azas N. Screening of selected indigenous plants of Cambodia for antiplasmodial activity. *J Ethnopharmacol* 2006; 107: 12-18.
- [8] Kumaran A, Karunakaran RJ. In vitro antioxidant activities of methanol extracts of five *Phyllanthus* species from India. *LWT - Food Science and Technology* 2007; 40: 344-352.
- [9] Giridharan P, Somasundaram ST, Perumal K, Vishwakarma RA, Karthikeyan NP, Velmurugan R, Balakrishnan A. Novel substituted methylenedioxy lignan suppresses proliferation of cancer cells by inhibiting telomerase and activation of c-myc and caspases leading to apoptosis. *Br J Cancer* 2002; 87: 98-105.
- [10] Fang SH, Rao YK, Tzeng YM. Anti-oxidant and inflammatory mediator's growth inhibitory effects of compounds isolated from *Phyllanthus urinaria*. *J Ethnopharmacol* 2008; 116: 333-340.
- [11] Lai CH, Fang SH, Rao YK, Geethangili M, Tang CH, Lin YJ, Hung CH, Wang WC, Tzeng YM. Inhibition of *Helicobacter pylori*-induced inflammation in human gastric epithelial AGS cells by *Phyllanthus urinaria* extracts. *J Ethnopharmacol* 2008; 118: 522-526.
- [12] Blumberg BS, Millman I, Venkateswaran PS, Thyagarajan SP. Hepatitis B virus and primary hepatocellular carcinoma: treatment of HBV carriers with *Phyllanthus amarus*. *Vaccine* 1990; 8 Suppl: S86-92.
- [13] Lee CD, Ott M, Thyagarajan SP, Shafritz DA, Burk RD, Gupta S. *Phyllanthus amarus* down-regulates hepatitis B virus mRNA transcription and replication. *Eur J Clin Invest* 1996; 26: 1069-1076.
- [14] Lv JJ, Wang YF, Zhang JM, Yu S, Wang D, Zhu HT, Cheng RR, Yang CR, Xu M, Zhang YJ. Anti-hepatitis B virus activities and absolute configurations of sesquiterpenoid glycosides from *Phyllanthus emblica*. *Org Biomol Chem* 2014; 12: 8764-8774.
- [15] Alvarez AL, Dalton KP, Nicieza I, Dineiro Y, Picinelli A, Melon S, Roque A, Suarez B, Parra F. Bioactivity-guided fractionation of *Phyllanthus orbicularis* and identification of the principal anti HSV-2 compounds. *Phytother Res* 2012; 26: 1513-1520.
- [16] Yang CM, Cheng HY, Lin TC, Chiang LC, Lin CC. Acetone, ethanol and methanol extracts of *Phyllanthus urinaria* inhibit HSV-2 infection in vitro. *Antiviral Res* 2005; 67: 24-30.
- [17] Yang CM, Cheng HY, Lin TC, Chiang LC, Lin CC. *Euphorbia thymifolia* suppresses herpes simplex virus-2 infection by directly inactivating virus infectivity. *Clin Exp Pharmacol Physiol* 2005; 32: 346-349.
- [18] Yang CM, Cheng HY, Lin TC, Chiang LC, Lin CC. The in vitro activity of geraniin and 1,3,4,6-tetra-O-galloyl-beta-D-glucose isolated from *Phyllanthus urinaria* against herpes simplex virus type 1 and type 2 infection. *J Ethnopharmacol* 2007; 110: 555-558.
- [19] Yang CM, Cheng HY, Lin TC, Chiang LC, Lin CC. Hippomanin A from acetone extract of *Phyllanthus urinaria* inhibited HSV-2 but not HSV-1 infection in vitro. *Phytother Res* 2007; 21: 1182-1186.
- [20] Lee SH, Tang YQ, Rathkrishnan A, Wang SM, Ong KC, Manikam R, Payne BJ, Jaganath IB, Sekaran SD. Effects of cocktail of four local Malaysian medicinal plants (*Phyllanthus* spp.) against dengue virus 2. *BMC Complement Altern Med* 2013; 13: 192.
- [21] Yeo SG, Song JH, Hong EH, Lee BR, Kwon YS, Chang SY, Kim SH, Lee SW, Park JH, Ko HJ. Antiviral effects of *Phyllanthus urinaria* containing corilagin against human enterovirus 71 and Coxsackievirus A16 in vitro. *Arch Pharm Res* 2015; 38: 193-202.
- [22] Chung CY, Liu CH, Burnouf T, Wang GH, Chang SP, Jassey A, Tai CJ, Tai CJ, Huang CJ, Richardson CD, Yen MH, Lin CC, Lin LT. Activity-based

- and fraction-guided analysis of *Phyllanthus urinaria* identifies loliolide as a potent inhibitor of hepatitis C virus entry. *Antiviral Res* 2016; 130: 58-68.
- [23] Qian-Cutrone J, Huang S, Trimble J, Li H, Lin PF, Alam M, Kloor SE, Kadow KF. Niruriside, a new HIV REV/RRE binding inhibitor from *Phyllanthus niruri*. *J Nat Prod* 1996; 59:196-199.
- [24] Notka F, Meier GR, Wagner R. Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by *Phyllanthus amarus*. *Antiviral Res* 2003; 58: 175-186.
- [25] Hnatyszyn O, Broussalis A, Herrera G, Muschetti L, Coussio J, Martino V, Ferraro G, Font M, Monge A, Martínez-Irujo JJ. Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. *Phytother Res* 1999; 13: 206-209.
- [26] Latha P, Chaitanya D, Rukkumani R. Protective effect of *Phyllanthus niruri* on alcohol and heated sunflower oil induced hyperlipidemia in Wistar rats. *Toxicol Mech Methods* 2010; 20: 498-503.
- [27] Surya NB, Latha P, Rukkumani R. Protective effects of *Phyllanthus amarus* on fibrotic markers during alcohol and polyunsaturated fatty acid-induced toxicity. *Toxicol Mech Methods* 2011; 21: 48-52.
- [28] Guo Q, Zhang QQ, Chen JQ, Zhang W, Qiu HC, Zhang ZJ, Liu BM, Xu FG. Liver metabolomics study reveals protective function of *Phyllanthus urinaria* against CCl₄-induced liver injury. *Chin J Nat Med* 2017; 15: 525-533.
- [29] Higashino H, Suzuki A. A trial of chronic administration of Siamese *Momordica charantia* and *Phyllanthus urinaria* powders to streptozotocin-induced diabetic rats. *Acta Med Kinki Univ* 1995; 20: 97-101.
- [30] Haslinda MS, Aiyub Z, Bakar NK, Tohar N, Musa Y, Abdullah NR, Ibrahim H, Awang K. In vitro antiplasmodial activity, macronutrients and trace metals in the medicinal plants: *Phyllanthus* spp. and *Alpinia conchigera* Griff. *Trop Biomed* 2015; 32: 129-139.
- [31] Bae KH, Yun PY, Choi YE. Induction and in vitro proliferation of adventitious roots in *Phyllanthus urinaria*. *Korean Journal of Plant Resources* 2009; 22: 454-460.
- [32] Gunawan-Puteri M, Kato E, Kawabata J. α -Amylase inhibitors from an Indonesian medicinal herb, *Phyllanthus urinaria*. *J Sci Food Agric* 2012; 92: 606-609.
- [33] Lans CA. Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. *J Ethnobiol Ethnomed* 2006; 2: 45.
- [34] Yao QQ, Zuo CX. [Chemical studies on the constituents of *Phyllanthus urinaria* L.]. *Yao Xue Xue Bao* 1993; 28: 829-835.
- [35] Xu M, Zha ZJ, Qin XL, Zhang XL, Yang CR, Zhang YJ. Phenolic antioxidants from the whole plant of *Phyllanthus urinaria*. *Chem Biodivers* 2007; 4: 2246-2252.
- [36] Tseng HH, Chen PN, Kuo WH, Wang JW, Chu SC, Hsieh YS. Antimetastatic potentials of *Phyllanthus urinaria* L on A549 and Lewis lung carcinoma cells via repression of matrix-degrading proteases. *Integr Cancer Ther* 2012; 11: 267-278.
- [37] Wu C, Wei CS, Yu SF, Liu BL, Li YL, Ye WC, Tong GD, Zhou GX. Two new acetylated flavonoid glycosides from *Phyllanthus urinaria*. *J Asian Nat Prod Res* 2013; 15: 703-707.
- [38] Zhang LZ, Guo YJ, Tu GZ, Miao F, Guo WB. [Isolation and identification of a novel polyphenolic compound from *Phyllanthus urinaria* L.]. *Zhongguo Zhong Yao Za Zhi* 2000; 25: 724-725.
- [39] Zhang LZ, Guo YJ, Tu GZ, Guo WB, Miao F. Isolation and identification of a novel ellagitannin from *Phyllanthus urinaria* L. *Yao Xue Xue Bao* 2004; 39: 119-122.
- [40] Cheng HY, Yang CM, Lin TC, Lin LT, Chiang LC, Lin CC. Excoecarianin, isolated from *Phyllanthus urinaria* Linnaea, inhibits herpes simplex virus type 2 infection through inactivation of viral particles. *Evid Based Complement Alternat Med* 2011; 2011: 259103.
- [41] Huang ST, Wang CY, Yang RC, Chu CJ, Wu HT, Pang JH. *Phyllanthus urinaria* increases apoptosis and reduces telomerase activity in human nasopharyngeal carcinoma cells. *Forsch Komplementmed* 2009; 16: 34-40.
- [42] Ikeda M, Nagata T, Fujioka T, Yoshimura Y, Ishimaru K. Regulation of polyphenol metabolism by PAP2 gene integration: polyphenol production in *Phyllanthus urinaria*. *Japanese Journal of Food Chemistry* 2010; 17: 36-40.
- [43] Zhang LZ, Guo YJ, Tu GZ, Guo WB, Miao F. [Studies on chemical constituents of *Phyllanthus urinaria* L.]. *Zhongguo Zhong Yao Za Zhi* 2000; 25: 615-617.
- [44] Hu ZX, Lai Y, Zhang J, Wu Y, Luo Z, Yao G, Xue Y, Zhang Y. Phytochemical and chemotaxonomic studies on *Phyllanthus urinaria*. *Biochem Syst Ecol* 2014; 56: 60-64.
- [45] Wang CY, Lee SS. Analysis and identification of lignans in *Phyllanthus urinaria* by HPLC-SPE-NMR. *Phytochem Anal* 2005; 16: 120-126.
- [46] Wu Y, Xie SS, Hu ZX, Wu ZD, Guo Y, Zhang JW, Wang JP, Xue YB, Zhang YH. Triterpenoids from whole plants of *Phyllanthus urinaria*. *Chinese Herbal Medicines* 2017; 9: 193-196.
- [47] Tsai K, Kuo C, Ou J. Mechanisms of Hepatitis B virus persistence. *Trends Microbiol* 2018; 26: 33-42.
- [48] Ji XH, Qin YZ, Wang WY, Zhu JY, Liu XT. [Effects of extracts from *Phyllanthus urinaria* L. on HBsAg production in PLC/PRF/5 cell line]. *Zhong-*

- guo Zhong Yao Za Zhi 1993; 18: 496-498, 511.
- [49] Zhong Y, Zuo C, Li F, Ding X, Yao Q, Wu K, Zhang Q, Wang Z, Zhou LW, Lan J, Wang X. [Chemical constituents of *Phyllanthus urinaria* L. and its antiviral activity against hepatitis B virus]. Zhongguo Zhong Yao Za Zhi 1998; 23: 363-364, 384.
- [50] Wu Y, Lu Y, Li SY, Song YH, Hao Y, Wang Q. Extract from *Phyllanthus urinaria* L. inhibits hepatitis B virus replication and expression in hepatitis B virus transfection model in vitro. Chin J Integr Med 2015; 21: 938-943.
- [51] Jung J, Kim NK, Park S, Shin HJ, Hwang SG, Kim K. Inhibitory effect of *Phyllanthus urinaria* L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro. BMC Complement Altern Med 2015; 15: 255.
- [52] Lu YH, Fu LC. Experimental study on the Anti-HBV activity of compound *Phyllanthus urinaria* in vitro. China Tropical Medicine 2007; 2: 196-197, 203.
- [53] Chen YX, Guo SH, Zhang DF. [Experimental study on anti-duck hepatitis B viral effect of *Phyllanthus urinaria* of different areas and combined therapy with other drugs]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995; 15: 225-227.
- [54] Wang M, Cheng H, Li Y, Meng L, Zhao G, Mai K. Herbs of the genus *Phyllanthus* in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. J Lab Clin Med 1995; 126: 350-352.
- [55] Tong GD, Zhang X, Zhou DQ, Wei CS, He JS, Xiao CL, Liu XL, Zheng YJ, Chen SN, Tang HH. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound *Phyllanthus urinaria* L. Chin J Integr Med 2014; 20: 263-271.
- [56] Shin MS, Kang EH, Lee YI. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res 2005; 67: 163-168.
- [57] Kurt-Jones EA, Orzalli MH, Knipe DM. Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease. Adv Anat Embryol Cell Biol 2017; 223: 49-75.
- [58] Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357: 1513-1518.
- [59] James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res 2009; 83: 207-213.
- [60] Guo YJ, Zhao L, Li XF, Mei YW, Zhang SL, Tao JY, Zhou Y, Dong JH. Effect of Corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglia. Eur J Pharmacol 2010; 635: 79-86.
- [61] Guo YJ, Luo T, Wu F, Liu H, Li HR, Mei YW, Zhang SL, Tao JY, Dong JH, Fang Y, Zhao L. Corilagin protects against HSV1 encephalitis through inhibiting the TLR2 signaling pathways in vivo and in vitro. Mol Neurobiol 2015; 52: 1547-1560.
- [62] Tan WC, Jaganath IB, Manikam R, Sekaran SD. Evaluation of antiviral activities of four local Malaysian *Phyllanthus* species against herpes simplex viruses and possible antiviral target. Int J Med Sci 2013; 10: 1817-1829.
- [63] Thrift AP, Elserag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 2017; 14: 122-132.
- [64] McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10: 11-23.
- [65] Zhang XX, Xia Q, Yang GH, Zhu D, Shao YY, Zhang JY, Cui YP, Wang RF, Zhang LZ. The anti-HIV-1 activity of polyphenols from *Phyllanthus urinaria* and the pharmacokinetics and tissue distribution of its marker compound, gallic acid. Journal of Traditional Chinese Medical Sciences 2017; 4: 158-166.
- [66] Liu KC, Lin MT, Lee SS, Chiou JF, Ren S, Lien EJ. Antiviral tannins from two *Phyllanthus* species. Planta Med 1999; 65: 43-46.
- [67] Huang ST, Pang JH, Yang RC. Anti-cancer effects of *Phyllanthus urinaria* and relevant mechanisms. Chang Gung Med J 2010; 33: 477-487.
- [68] Huang ST, Yang RC, Yang LJ, Lee PN, Pang JH. *Phyllanthus urinaria* triggers the apoptosis and Bcl-2 down-regulation in Lewis lung carcinoma cells. Life Sci 2003; 72: 1705-1716.
- [69] Huang ST, Yang RC, Lee PN, Yang SH, Liao SK, Chen TY, Pang JH. Anti-tumor and anti-angiogenic effects of *Phyllanthus urinaria* in mice bearing Lewis lung carcinoma. Int Immunopharmacol 2006; 6: 870-879.
- [70] Huang ST, Huang CC, Sheen JM, Lin TK, Liao PL, Huang WL, Wang PW, Liou CW, Chuang JH. *Phyllanthus urinaria*'s inhibition of human osteosarcoma xenografts growth in mice is associated with modulation of mitochondrial fission/fusion machinery. Am J Chin Med 2016; 44: 1507-1523.
- [71] Huang ST, Yang RC, Pang JH. Aqueous extract of *Phyllanthus urinaria* induces apoptosis in human cancer cells. Am J Chin Med 2004; 32: 175-183.
- [72] Lee SH, Jaganath IB, Manikam R, Sekaran SD. Inhibition of Raf-MEK-ERK and hypoxia pathways by *Phyllanthus* prevents metastasis in hu-

- man lung (A549) cancer cell line. *BMC Complement Altern Med* 2013; 13: 271.
- [73] Lee SH, Jaganath IB, Wang SM, Sekaran SD. Antimetastatic effects of *Phyllanthus* on human lung (A549) and breast (MCF-7) cancer cell lines. *PLoS One* 2011; 6: e20994.
- [74] Huang ST, Wang CY, Yang RC, Wu HT, Yang SH, Cheng YC, Pang JH. Ellagic acid, the active compound of *Phyllanthus urinaria*, exerts in vivo anti-angiogenic effect and inhibits MMP-2 activity. *Evid Based Complement Alternat Med* 2011; 2011: 215035.
- [75] Tang YQ, Jaganath IB, Manikam R, Sekaran SD. *Phyllanthus* spp. exerts anti-angiogenic and anti-metastatic effects through inhibition on matrix metalloproteinase enzymes. *Nutr Cancer* 2015; 67: 783-795.
- [76] Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. *Front Oncol* 2017; 7: 193.
- [77] Lin Y, Jewell B, Gingold J, Lu L, Zhao R, Wang L, Lee D. Osteosarcoma: molecular pathogenesis and iPSC modeling. *Trends Mol Med* 2017; 23: 737-755.
- [78] Wu HY, Lin TK, Kuo HM, Huang YL, Liou CW, Wang PW, Chuang JH, Huang ST. *Phyllanthus urinaria* induces apoptosis in human osteosarcoma 143B cells via activation of Fas/FasL and mitochondria-mediated pathways. *Evid Based Complement Alternat Med* 2012; 2012: 925824.
- [79] Lu KH, Yang HW, Su CW, Lue KH, Yang SF, Hsieh YS. *Phyllanthus urinaria* suppresses human osteosarcoma cell invasion and migration by transcriptionally inhibiting u-PA via ERK and Akt signaling pathways. *Food Chem Toxicol* 2013; 52: 193-199.
- [80] Huang ST, Bi KW, Kuo HM, Lin TK, Liao PL, Wang PW, Chuang JH, Liou CW. *Phyllanthus urinaria* induces mitochondrial dysfunction in human osteosarcoma 143B cells associated with modulation of mitochondrial fission/fusion proteins. *Mitochondrion* 2014; 17: 22-33.
- [81] Cosgarea I, Ritter C, Becker J, Schadendorf D, Ugurel S. Update on the clinical use of kinase inhibitors in melanoma. *J Dtsch Dermatol Ges* 2017; 15: 887-893.
- [82] Arung ET, Kusuma IW, Christy EO, Shimizu K, Kondo R. Evaluation of medicinal plants from Central Kalimantan for antimelanogenesis. *J Nat Med* 2009; 63: 473-480.
- [83] Tang YQ, Jaganath IB, Manikam R, Sekaran SD. Inhibition of MAPKs, Myc/Max, NFkappaB, and hypoxia pathways by *Phyllanthus* prevents proliferation, metastasis and angiogenesis in human melanoma (MeWo) cancer cell line. *Int J Med Sci* 2014; 11: 564-577.
- [84] Bharali R, Tabassum J, Azad MR. Chemopreventive action of *Phyllanthus urinaria* Linn on DMBA-induced skin carcinogenesis in mice. *Indian J Exp Biol* 2003; 41: 1325-1328.
- [85] El-Serag HB. Hepatocellular carcinoma. *N Engl J Med* 2011; 365: 1118-1127.
- [86] Chudapongse N, Kamkhunthod M, Poompachee K. Effects of *Phyllanthus urinaria* extract on HepG2 cell viability and oxidative phosphorylation by isolated rat liver mitochondria. *J Ethnopharmacol* 2010; 130: 315-319.
- [87] Phi XA, Houssami N, Hooning MJ, Riedl CC, Leach MO, Sardanelli F, Warner E, Trop I, Saadatmand S, Tilanus-Linthorst MMA, Helbich TH, van den Heuvel ER, de Koning HJ, Obdeijn IM, de Bock GH. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. *Eur J Cancer* 2017; 85: 31-38.
- [88] Zhai JW, Gao C, Ma WD, Wang W, Yao LP, Xia XX, Luo M, Zu YG, Fu YJ. Geraniin induces apoptosis of human breast cancer cells MCF-7 via ROS-mediated stimulation of p38 MAPK. *Toxicol Mech Methods* 2016; 26: 311-318.
- [89] Kim K, Kim J. Intervention for patient reported urinary symptoms in prostate cancer survivors: systematic review. *J Cancer Surviv* 2017; 11: 643-654..
- [90] Tang YQ, Jaganath IB, Sekaran SD. *Phyllanthus* spp. induces selective growth inhibition of PC-3 and MeWo human cancer cells through modulation of cell cycle and induction of apoptosis. *PLoS One* 2010; 5: e12644.
- [91] Kim K, Le Q, Yom S, Ng R, Chan K, Bratman S, Welch J, Divi R, Petryshyn R, Conley B. Clinical utility of Epstein-Barr virus DNA testing in the treatment of nasopharyngeal carcinoma patients. *Int J Radiat Oncol Biol Phys* 2017; 98: 996-1001.
- [92] Srirama R, Senthilkumar U, Sreejayan N, Ravikanth G, Gurumurthy BR, Shivanna MB, Sanjappa M, Ganeshiah KN, Shaanker RU. Assessing species admixtures in raw drug trade of *Phyllanthus*, a hepato-protective plant using molecular tools. *J Ethnopharmacol* 2010; 130: 208-215.
- [93] Srirama R, Deepak HB, Senthilkumar U, Ravikanth G, Gurumurthy BR, Shivanna MB, Chandrasekaran CV, Agarwal A, Shaanker RU. Hepatoprotective activity of Indian *Phyllanthus*. *Pharm Biol* 2012; 50: 948-953.
- [94] Zhou S, Xu C, Zhou N, Huang Y, Huang L, Chen X, Hu Y, Liao Y. [Mechanism of protective action of *Phyllanthus urinaria* L. against injuries of liver cells]. *Zhongguo Zhong Yao Za Zhi* 1997; 22: 109-111; inside back cover.
- [95] Lee CY, Peng WH, Cheng HY, Chen FN, Lai MT, Chiu TH. Hepatoprotective effect of *Phyllanthus* in Taiwan on acute liver damage induced by carbon tetrachloride. *Am J Chin Med* 2006; 34: 471-482.

- [96] Hau DK, Gambari R, Wong RS, Yuen MC, Cheng GY, Tong CS, Zhu GY, Leung AK, Lai PB, Lau FY, Chan AK, Wong WY, Kok SH, Cheng CH, Kan CW, Chan AS, Chui CH, Tang JC, Fong DW. *Phyllanthus urinaria* extract attenuates acetaminophen induced hepatotoxicity: involvement of cytochrome P450 CYP2E1. *Phytomedicine* 2009; 16: 751-760.
- [97] Sharma SK, Arogya SM, Bhaskarmurthy DH, Agarwal A, Velusami CC. Hepatoprotective activity of the *Phyllanthus* species on tert-butyl hydroperoxide (t-BH)-induced cytotoxicity in HepG2 cells. *Pharmacogn Mag* 2011; 7: 229-233.
- [98] Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, Lin G, Sung JJ, Chan HL. *Phyllanthus urinaria* ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. *Hepatology* 2008; 47: 473-483.
- [99] Syamasundar KV, Singh B, Thakur RS, Husain A, Kiso Y, Hikino H. Antihepatotoxic principles of *Phyllanthus niruri* herbs. *J Ethnopharmacol* 1985; 14: 41.
- [100] Liu FC, Chaudry IH, Yu HP. Hepatoprotective effects of Corilagin following hemorrhagic shock are through akt-dependent pathway. *Shock* 2017; 47: 346-351.
- [101] Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL. Treatment of non-alcoholic steatohepatitis with *Phyllanthus urinaria*: a randomized trial. *J Gastroenterol Hepatol* 2013; 28: 57-62.
- [102] Trinh BTD, Staerk D, Jager AK. Screening for potential alpha-glucosidase and alpha-amylase inhibitory constituents from selected Vietnamese plants used to treat type 2 diabetes. *J Ethnopharmacol* 2016; 186:189-195.
- [103] Higashino H, Suzuki A, Tanaka Y, Pootakham K. [Hypoglycemic effects of Siamese *Momordica charantia* and *Phyllanthus urinaria* extracts in streptozotocin-induced diabetic rats (the 1st report)]. *Nihon Yakurigaku Zasshi* 1992; 100: 415-421.
- [104] Akhtar MN, Gayathri M. Anti-oxidant, anti-microbial and glucose diffusion inhibition activities of the aqueous and chloroform extract of *phyllanthus urinaria*. *International Journal of Pharmacy and Pharmaceutical Sciences* 2016.
- [105] Neamsuvan O, Bunmee P. A survey of herbal weeds for treating skin disorders from Southern Thailand: Songkhla and Krabi Province. *J Ethnopharmacol* 2016; 193: 574-585.
- [106] Mahdi ES, Noor AM, Sakeena MH, Abdullah GZ, Abdulkarim MF, Sattar MA. Formulation and in vitro release evaluation of newly synthesized palm kernel oil esters-based nanoemulsion delivery system for 30% ethanolic dried extract derived from local *Phyllanthus urinaria* for skin antiaging. *Int J Nanomedicine* 2011; 6: 2499-2512.
- [107] Chularojmontri L, Ihara Y, Muroi E, Goto S, Kondo T, Wattanapitayakul SK. Cytoprotective role of *Phyllanthus urinaria* L. and glutathione-S transferase Pi in doxorubicin-induced toxicity in H9c2 cells. *J Med Assoc Thai* 2009; 92 Suppl 3: S43-51.
- [108] Yuandani, Ilangkovan M, Jantan I, Mohamad HF, Husain K, Abdul Razak AF. Inhibitory effects of standardized extracts of *Phyllanthus amarus* and *Phyllanthus urinaria* and their marker compounds on phagocytic activity of human neutrophils. *Evid Based Complement Alternat Med* 2013; 2013: 603634.
- [109] Dias MA, Campos AH, Cechinel Filho V, Yunes RA, Calixto JB. Analysis of the mechanisms underlying the contractile response induced by the hydroalcoholic extract of *Phyllanthus urinaria* in the guinea-pig urinary bladder in-vitro. *J Pharm Pharmacol* 1995; 47: 846-851.